| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCNH2 |
| Uniprot No | P11308 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-486aa |
| 活性数据 | MIQTVPDPAAHIKEALSVVSEDQSLFECAYGTPHLAKTEMTASSSSDYGQTSKMSPRVPQQDWLSQPPARVTIKMECNPSQVNGSRNSPDECSVAKGGKMVGSPDTVGMNYGSYMEEKHMPPPNMTTNERRVIVPADPTLWSTDHVRQWLEWAVKEYGLPDVNILLFQNIDGKELCKMTKDDFQRLTPSYNADILLSHLHYLRETPLPHLTSDDVDKALQNSPRLMHARNTGGAAFIFPNTSVYPEATQRITTRPDLPYEPPRRSAWTGHGHPTPQSKAAQPSPSTVPKTEDQRPQLDPYQILGPTSSRLANPGSGQIQLWQFLLELLSDSSNSSCITWEGTNGEFKMTDPDEVARRWGERKSKPNMNYDKLSRALRYYYDKNIMTKVHGKRYAYKFDFHGIAQALQPHPPESSLYKYPSDLPYMGSYHAHPQKMNFVAPHPPALPVTSSSFFAAPNPYWNSPTGGIYPNTRLPTSHMPSHLGTYY |
| 分子量 | 56.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人KCNH2(hERG)蛋白的参考文献及其摘要，按研究领域分类列举：
---
1. **文献名称**：*Crystal Structure of the Human KCNH2 (hERG) Potassium Ion Channel*
**作者**：Whicher, J.R. & MacKinnon, R.
**摘要**：通过冷冻电镜技术解析了hERG通道的闭合状态结构，揭示了其独特的电压敏感结构域和选择性滤过器特征，解释了hERG在心脏动作电位复极化中的关键作用及药物结合位点。
2. **文献名称**：*Mechanism of hERG Channel Block by the Antihistamine Astemizole*
**作者**：Zhou, Z., et al.
**摘要**：研究阿司咪唑对重组hERG通道的阻断机制，发现其通过结合通道中央空腔并干扰S6螺旋运动抑制钾离子流，为药物心脏毒性评估提供了分子依据。
3. **文献名称**：*hERG Missense Mutations Disrupt Channel Trafficking and Gating in Long QT Syndrome*
**作者**：Anderson, C.L., et al.
**摘要**：分析长QT综合征相关hERG错义突变，发现突变体因错误折叠滞留于内质网或门控异常导致功能丧失，强调了重组蛋白模型在疾病机制研究中的应用。
4. **文献名称**：*Temperature-Sensitive Trafficking of hERG Channels Links Cardiac Ion Channelopathies*
**作者**：Zhou, Z., et al.
**摘要**：发现温度调控重组hERG通道的膜表达，部分突变体在低温下功能恢复，提示热休克蛋白参与折叠调控，为基因治疗提供潜在靶点。
---
**研究方向覆盖**：结构生物学、药物相互作用、疾病突变机制及治疗策略。经典文献多聚焦hERG在心脏电生理及药物研发中的双重重要性。
The human KCNH2 gene encodes the human ether-à-go-go-related gene (hERG) protein, a voltage-gated potassium channel critical for cardiac action potential repolarization. As a key component of the rapid delayed rectifier potassium current (IKr), hERG ensures proper electrical signaling in the heart by regulating the flow of K⁺ ions during membrane depolarization and repolarization. Mutations in KCNH2 are linked to Long QT syndrome type 2 (LQT2), a cardiac disorder characterized by prolonged ventricular repolarization, arrhythmias, and sudden death. Additionally, hERG channels are a well-known target for drug-induced cardiotoxicity, as many pharmaceuticals inadvertently block these channels, disrupting normal cardiac rhythms.
Recombinant human KCNH2 protein is produced using heterologous expression systems (e.g., HEK293 cells, Xenopus oocytes) to study channel function, structure, and pharmacology in vitro. Its expression allows researchers to characterize ion channel kinetics, screen for potential therapeutics, and investigate mechanisms underlying channelopathies. The protein typically includes the six transmembrane domains and pore-forming region critical for ion selectivity, along with cytoplasmic N- and C-terminal domains involved in channel gating and regulation. Structural studies of recombinant hERG have advanced understanding of its unique inactivation properties and interactions with small molecules. This protein is indispensable for cardiac safety assessments in drug development and for developing targeted treatments for arrhythmia-related disorders.
×
